{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T20:26:21Z","timestamp":1793132781518,"version":"4.5.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Capital Clinical Diagnostic Techniques and Translational Application Projects","award":["Z211100002921059"],"award-info":[{"award-number":["Z211100002921059"]}]},{"name":"National Key Research and Development Program of Ministry of Science and Technology","award":["2023YFC2308100"],"award-info":[{"award-number":["2023YFC2308100"]}]},{"DOI":"10.13039\/501100012435","name":"Project of High-level Teachers in Beijing Municipal Universities in the Period of 13th Five-year Plan","doi-asserted-by":"publisher","award":["Academic Leader-02-14"],"award-info":[{"award-number":["Academic Leader-02-14"]}],"id":[{"id":"10.13039\/501100012435","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["7222093"],"award-info":[{"award-number":["7222093"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and aim<\/jats:title>\n                    <jats:p>To identify predictive factors for rapid hepatitis B surface antigen (HBsAg) seroclearance at week 24 in inactive HBsAg carriers (IHC) receiving pegylated interferon alpha-2b (Peg-IFN) therapy, and to develop a machine learning-based model to optimize individualized treatment strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This retrospective analysis was based on a multicenter, prospective cohort study involving 2882 IHC patients treated with Peg-IFN and followed for at least 24\u00a0weeks. Predictive variables for week 24 HBsAg seroclearance were selected using both LASSO regression and the Boruta algorithm. Nine machine learning models were developed, including logistic regression (LR), decision tree (DT), and random forest (RF), with performance assessed via tenfold cross-validation. External validation was conducted in an independent cohort (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009167) from three medical centers in Beijing. SHapley Additive Explanations (SHAP) were used to interpret model predictions and feature importance.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The overall HBsAg seroclearance rate at week 24 was 18.7% (541\/2,882). Key predictive factors included baseline HBsAg level,\u2009\u2265\u20091 log IU\/mL decline in HBsAg at week 12, the ratio of alanine aminotransferase (ALT) to HBsAg at week 12, the ratio of week 12 ALT to baseline HBsAg, week 12 hepatitis B virus (HBV) DNA level, and week 12 hepatitis B surface antibody (HBsAb) level. The Light Gradient Boosting Machine (Light GBM) model demonstrated the best performance, achieving an area under the receiver operating characteristic curve (AUC) of 0.902 (95% CI 0.881\u20130.923) and a sensitivity of 0.889 in the training cohort, and an AUC of 0.917 (95% CI 0.850\u20130.983) with a sensitivity of 0.879 in the external validation cohort. SHAP analysis revealed that the week 12 ALT\/ HBsAg ratio was the most impactful feature.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We developed a LightGBM-based machine learning model that accurately predicts rapid HBsAg seroclearance at week 24 among IHC patients receiving Peg-IFN therapy. This model offers a valuable tool for early identification of rapid responders, personalized treatment planning, and potential discontinuation strategies. The individualized stopping rules derived from model-predicted probabilities provide an evidence-based approach to precision therapy in IHC patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12072-025-10936-x","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T20:43:57Z","timestamp":1763412237000},"page":"1331-1346","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Machine learning prediction of rapid HBsAg seroclearance at week 24 in inactive carriers treated with pegylated interferon"],"prefix":"10.1007","volume":"19","author":[{"given":"Jianxia","family":"Dong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengxuan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitian","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyue","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyang","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zujiang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilan","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaozhong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haibing","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuangsuo","family":"Dang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiabin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujun","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyue","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,17]]},"reference":[{"key":"10936_CR1","unstructured":"Organization. WH. WHO sounds alarm on viral hepatitis infections claiming 3500 lives each day. 2024. https:\/\/www.who.int\/news\/item\/09-04-2024-who-sounds-alarm-on-viral-hepatitis-infections-claiming-3500-lives-each-day. Accessed on 4 Sept 2024"},{"issue":"4","key":"10936_CR2","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.29800","volume":"67","author":"NA Terrault","year":"2018","unstructured":"Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560\u20131599. https:\/\/doi.org\/10.1002\/hep.29800","journal-title":"Hepatology"},{"issue":"10","key":"10936_CR3","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/s2468-1253(21)00267-3","volume":"6","author":"P Easterbrook","year":"2021","unstructured":"Easterbrook P, Luhmann N, Newman M, Walsh N, Lesi O, Doherty M. New WHO guidance for country validation of viral hepatitis B and C elimination. Lancet Gastroenterol Hepatol. 2021;6(10):778\u2013780. https:\/\/doi.org\/10.1016\/s2468-1253(21)00267-3","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10936_CR4","doi-asserted-by":"publisher","unstructured":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370\u2013398. https:\/\/doi.org\/10.1016\/j.jhep.2017.03.021.","DOI":"10.1016\/j.jhep.2017.03.021"},{"issue":"1","key":"10936_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s12985-025-02853-0","volume":"22","author":"S Ren","year":"2025","unstructured":"Ren S, Zheng S, Zhang X, et al. Reevaluating antiviral thresholds in HBV DNA-negative inactive HBsAg carriers: a multicenter histopathological analysis. Virol J. 2025;22(1): 235. https:\/\/doi.org\/10.1186\/s12985-025-02853-0","journal-title":"Virol J"},{"issue":"5","key":"10936_CR6","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1053\/j.gastro.2010.01.042","volume":"138","author":"JD Chen","year":"2010","unstructured":"Chen JD, Yang HI, Iloeje UH, et al. Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death. Gastroenterology. 2010;138(5):1747\u20131754. https:\/\/doi.org\/10.1053\/j.gastro.2010.01.042","journal-title":"Gastroenterology"},{"issue":"1","key":"10936_CR7","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1001\/jama.295.1.65","volume":"295","author":"CJ Chen","year":"2006","unstructured":"Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295(1):65\u201373. https:\/\/doi.org\/10.1001\/jama.295.1.65","journal-title":"JAMA"},{"issue":"1","key":"10936_CR8","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s00535-016-1229-6","volume":"52","author":"T Taida","year":"2017","unstructured":"Taida T, Arai M, Kanda T, et al. The prognosis of hepatitis B inactive carriers in Japan: a multicenter prospective study. J Gastroenterol. 2017;52(1):113\u2013122. https:\/\/doi.org\/10.1007\/s00535-016-1229-6","journal-title":"J Gastroenterol"},{"issue":"9","key":"10936_CR9","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1111\/liv.14897","volume":"41","author":"F Wu","year":"2021","unstructured":"Wu F, Lu R, Liu Y, et al. Efficacy and safety of peginterferon alpha monotherapy in Chinese inactive chronic hepatitis B virus carriers. Liver Int. 2021;41(9):2032\u20132045. https:\/\/doi.org\/10.1111\/liv.14897","journal-title":"Liver Int"},{"key":"10936_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.779347","volume":"12","author":"A Song","year":"2021","unstructured":"Song A, Lin X, Lu J, et al. Pegylated interferon treatment for the effective clearance of hepatitis B surface antigen in inactive HBsAg carriers: a meta-analysis. Front Immunol. 2021;12: 779347. https:\/\/doi.org\/10.3389\/fimmu.2021.779347","journal-title":"Front Immunol"},{"issue":"7","key":"10936_CR11","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/s2468-1253(19)30119-0","volume":"4","author":"PA Revill","year":"2019","unstructured":"Revill PA, Chisari FV, Block JM, et al. A global scientific strategy to cure hepatitis B. Lancet Gastroenterol Hepatol. 2019;4(7):545\u2013558. https:\/\/doi.org\/10.1016\/s2468-1253(19)30119-0","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"10936_CR12","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.1007\/s40121-021-00511-w","volume":"10","author":"Y Huang","year":"2021","unstructured":"Huang Y, Qi M, Liao C, et al. Analysis of the efficacy and safety of PEGylated interferon-\u03b12b treatment in inactive hepatitis B surface antigen carriers. Infect Dis Ther. 2021;10(4):2323\u20132331. https:\/\/doi.org\/10.1007\/s40121-021-00511-w","journal-title":"Infect Dis Ther"},{"issue":"4","key":"10936_CR13","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1007\/s12072-024-10666-6","volume":"18","author":"PX Zhang","year":"2024","unstructured":"Zhang PX, Tang QQ, Zhu J, Deng WY, Zhang ZH. Predictive models for functional cure in patients with CHB receiving PEG-IFN therapy based on HBsAg quantification through meta-analysis. Hepatol Int. 2024;18(4):1110\u20131121. https:\/\/doi.org\/10.1007\/s12072-024-10666-6","journal-title":"Hepatol Int"},{"key":"10936_CR14","doi-asserted-by":"publisher","unstructured":"Global burden of 369 diseases and injuries in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1204\u20131222. https:\/\/doi.org\/10.1016\/s0140-6736(20)30925-9.","DOI":"10.1016\/s0140-6736(20)30925-9"},{"key":"10936_CR15","doi-asserted-by":"publisher","first-page":"4665","DOI":"10.12659\/msm.916441","volume":"25","author":"Q Chen","year":"2019","unstructured":"Chen Q, Zhang J, Huang J, et al. Early serum HBsAg drop is a strong predictor of HBeAg seroconversion and HBsAg loss to pegylated interferon alfa-2a in chronic hepatitis B patients with prior nucleos(t)ide analogue exposure. Med Sci Monit. 2019;25:4665\u20134674. https:\/\/doi.org\/10.12659\/msm.916441","journal-title":"Med Sci Monit"},{"issue":"13","key":"10936_CR16","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.3748\/wjg.v26.i13.1525","volume":"26","author":"FP Wu","year":"2020","unstructured":"Wu FP, Yang Y, Li M, et al. Add-on pegylated interferon augments hepatitis B surface antigen clearance vs continuous nucleos(t)ide analog monotherapy in Chinese patients with chronic hepatitis B and hepatitis B surface antigen \u2264 1500 IU\/mL: an observational study. World J Gastroenterol. 2020;26(13):1525\u20131539. https:\/\/doi.org\/10.3748\/wjg.v26.i13.1525","journal-title":"World J Gastroenterol"},{"issue":"13","key":"10936_CR17","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1056\/NEJMra2302038","volume":"388","author":"CJ Haug","year":"2023","unstructured":"Haug CJ, Drazen JM. Artificial intelligence and machine learning in clinical medicine, 2023. N Engl J Med. 2023;388(13):1201\u20131208. https:\/\/doi.org\/10.1056\/NEJMra2302038","journal-title":"N Engl J Med"},{"key":"10936_CR18","doi-asserted-by":"publisher","unstructured":"The guidelines of prevention and treatment for chronic hepatitis B (2019 version). Zhonghua Gan Zang Bing Za Zhi. 2019;27(12):938\u2013961. https:\/\/doi.org\/10.3760\/cma.j.issn.1007-3418.2019.12.007.","DOI":"10.3760\/cma.j.issn.1007-3418.2019.12.007"},{"issue":"4","key":"10936_CR19","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1002\/hep.29213","volume":"66","author":"Z Cao","year":"2017","unstructured":"Cao Z, Liu Y, Ma L, et al. A potent hepatitis B surface antigen response in subjects with inactive hepatitis B surface antigen carrier treated with pegylated-interferon alpha. Hepatology. 2017;66(4):1058\u20131066. https:\/\/doi.org\/10.1002\/hep.29213","journal-title":"Hepatology"},{"key":"10936_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.virusres.2024.199507","volume":"351","author":"J Zheng","year":"2025","unstructured":"Zheng J, Wang Z, Huang L, et al. Achieving chronic hepatitis B functional cure: factors and potential mechanisms. Virus Res. 2025;351: 199507. https:\/\/doi.org\/10.1016\/j.virusres.2024.199507","journal-title":"Virus Res"},{"issue":"1","key":"10936_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-023-08443-1","volume":"23","author":"Q Tang","year":"2023","unstructured":"Tang Q, Ye J, Zhang Y, et al. Establishment of a multi-parameter prediction model for the functional cure of HBeAg-negative chronic hepatitis B patients treated with pegylated interferon\u03b1 and decision process based on response-guided therapy strategy. BMC Infect Dis. 2023;23(1): 456. https:\/\/doi.org\/10.1186\/s12879-023-08443-1","journal-title":"BMC Infect Dis"},{"key":"10936_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.997608","volume":"13","author":"X Yang","year":"2022","unstructured":"Yang X, Zhang K, Xu Q, et al. Interferon add-on therapy increased clinical cure significantly for interferon-experienced chronic hepatitis B patients with low HBsAg. Front Immunol. 2022;13: 997608. https:\/\/doi.org\/10.3389\/fimmu.2022.997608","journal-title":"Front Immunol"},{"issue":"1","key":"10936_CR23","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.jhep.2024.02.017","volume":"81","author":"BC Narmada","year":"2024","unstructured":"Narmada BC, Khakpoor A, Shirgaonkar N, et al. Single-cell landscape of functionally cured chronic hepatitis B patients reveals activation of innate and altered CD4-CTL-driven adaptive immunity. J Hepatol. 2024;81(1):42\u201361. https:\/\/doi.org\/10.1016\/j.jhep.2024.02.017","journal-title":"J Hepatol"},{"issue":"2","key":"10936_CR24","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.jhep.2020.04.013","volume":"73","author":"I Tout","year":"2020","unstructured":"Tout I, Loureiro D, Mansouri A, Soumelis V, Boyer N, Asselah T. Hepatitis B surface antigen seroclearance: immune mechanisms, clinical impact, importance for drug development. J Hepatol. 2020;73(2):409\u2013422. https:\/\/doi.org\/10.1016\/j.jhep.2020.04.013","journal-title":"J Hepatol"},{"issue":"1","key":"10936_CR25","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jhep.2019.08.024","volume":"72","author":"H Wang","year":"2020","unstructured":"Wang H, Luo H, Wan X, et al. TNF-\u03b1\/IFN-\u03b3 profile of HBV-specific CD4 T cells is associated with liver damage and viral clearance in chronic HBV infection. J Hepatol. 2020;72(1):45\u201356. https:\/\/doi.org\/10.1016\/j.jhep.2019.08.024","journal-title":"J Hepatol"},{"issue":"5","key":"10936_CR26","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.29627","volume":"96","author":"L Wu","year":"2024","unstructured":"Wu L, Deng H, Feng X, et al. Interferon-\u03b3(+) Th1 activates intrahepatic resident memory T cells to promote HBsAg loss by inducing M1 macrophage polarization. J Med Virol. 2024;96(5): e29627. https:\/\/doi.org\/10.1002\/jmv.29627","journal-title":"J Med Virol"},{"key":"10936_CR27","doi-asserted-by":"publisher","first-page":"49","DOI":"10.11604\/pamj.2018.31.49.16296","volume":"31","author":"I Diallo","year":"2018","unstructured":"Diallo I, Ndiaye B, Fall CA, et al. Inactive hepatitis B carriers: outcomes of patients followed at H\u00f4pital Principal de Dakar, Senegal. Pan Afr Med J. 2018;31:49. https:\/\/doi.org\/10.11604\/pamj.2018.31.49.16296","journal-title":"Pan Afr Med J"},{"issue":"1","key":"10936_CR28","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2025.2475847","volume":"14","author":"B Jiang","year":"2025","unstructured":"Jiang B, Guan G, Zhao K, et al. Mechanisms underlying delayed loss of HBeAg and HBV DNA following HBsAg seroclearance in PEG-IFN\u03b1 treated patients of chronic hepatitis B. Emerg Microbes Infect. 2025;14(1): 2475847. https:\/\/doi.org\/10.1080\/22221751.2025.2475847","journal-title":"Emerg Microbes Infect"},{"issue":"13","key":"10936_CR29","doi-asserted-by":"publisher","first-page":"3043","DOI":"10.1016\/j.cgh.2019.09.038","volume":"18","author":"HW Lee","year":"2020","unstructured":"Lee HW, Park JY, Hong T, Park MS, Ahn SH. Efficacy of Lenvervimab, a recombinant human immunoglobulin, in treatment of chronic Hepatitis B virus infection. Clin Gastroenterol Hepatol. 2020;18(13):3043-3045.e1. https:\/\/doi.org\/10.1016\/j.cgh.2019.09.038","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10936_CR30","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2023.2259003","volume":"12","author":"S Yin","year":"2023","unstructured":"Yin S, Wan Y, Issa R, et al. The presence of baseline HBsAb-specific B cells can predict HBsAg or HBeAg seroconversion of chronic hepatitis B on treatment. Emerg Microbes Infect. 2023;12(2): 2259003. https:\/\/doi.org\/10.1080\/22221751.2023.2259003","journal-title":"Emerg Microbes Infect"},{"issue":"10381","key":"10936_CR31","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/s0140-6736(22)01468-4","volume":"401","author":"WJ Jeng","year":"2023","unstructured":"Jeng WJ, Papatheodoridis GV, Lok ASF. Hepatitis B. Lancet. 2023;401(10381):1039\u20131052. https:\/\/doi.org\/10.1016\/s0140-6736(22)01468-4","journal-title":"Lancet"},{"issue":"1","key":"10936_CR32","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jhep.2021.07.031","volume":"76","author":"H Xu","year":"2022","unstructured":"Xu H, Locarnini S, Wong D, et al. Role of anti-HBs in functional cure of HBeAg+ chronic hepatitis B patients infected with HBV genotype A. J Hepatol. 2022;76(1):34\u201345. https:\/\/doi.org\/10.1016\/j.jhep.2021.07.031","journal-title":"J Hepatol"},{"issue":"1","key":"10936_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s12985-024-02344-8","volume":"21","author":"Y Liu","year":"2024","unstructured":"Liu Y, Ren S, Ma L, et al. Peg-IFN\u03b1 combined with hepatitis B vaccination contributes to HBsAg seroconversion and improved immune function. Virol J. 2024;21(1): 77. https:\/\/doi.org\/10.1186\/s12985-024-02344-8","journal-title":"Virol J"},{"issue":"3","key":"10936_CR34","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.jhep.2018.10.014","volume":"70","author":"TC Yip","year":"2019","unstructured":"Yip TC, Wong GL, Chan HL, et al. HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues. J Hepatol. 2019;70(3):361\u2013370. https:\/\/doi.org\/10.1016\/j.jhep.2018.10.014","journal-title":"J Hepatol"},{"issue":"3","key":"10936_CR35","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.cgh.2020.05.041","volume":"19","author":"RT Anderson","year":"2021","unstructured":"Anderson RT, Choi HSJ, Lenz O, et al. Association between seroclearance of hepatitis B surface antigen and long-term clinical outcomes of patients with chronic hepatitis B virus infection: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2021;19(3):463\u2013472. https:\/\/doi.org\/10.1016\/j.cgh.2020.05.041","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10936_CR36","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1111\/jvh.13471","volume":"28","author":"A Song","year":"2021","unstructured":"Song A, Wang X, Lu J, et al. Durability of hepatitis B surface antigen seroclearance and subsequent risk for hepatocellular carcinoma: a meta-analysis. J Viral Hepat. 2021;28(4):601\u2013612. https:\/\/doi.org\/10.1111\/jvh.13471","journal-title":"J Viral Hepat"},{"issue":"20","key":"10936_CR37","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1161\/circulationaha.115.001593","volume":"132","author":"RC Deo","year":"2015","unstructured":"Deo RC. Machine learning in medicine. Circulation. 2015;132(20):1920\u20131930. https:\/\/doi.org\/10.1161\/circulationaha.115.001593","journal-title":"Circulation"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-025-10936-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-025-10936-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-025-10936-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T12:33:47Z","timestamp":1772195627000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12072-025-10936-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,17]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10936"],"URL":"https:\/\/doi.org\/10.1007\/s12072-025-10936-x","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,17]]},"assertion":[{"value":"31 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethical approval was obtained from the institutional review boards of all participating centers (Primary cohort: 2022-067-K; External cohort: 2022-047-K). The study adhered to the principles of the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was obtained from all participants prior to data collection. As this study involved a retrospective analysis of prospectively collected clinical data, the use of patient information was reviewed and approved by the institutional review boards of the participating centers in accordance with the ethical standards of the Declaration of Helsinki.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent"}}]}}